Adherium appoints Geoff Feakes as Chief Technology Officer

05 Aug 2020 | People

Melbourne, Australia – 5 August 2020: Adherium Limited (ASX: ADR) a leader in digital inhaled device adherence, remote monitoring and data management solutions, has appointed Mr Geoff Feakes as Chief Technology Officer (CTO) leading the Company’s R&D and Innovation teams supporting Adherium’s revised business strategy.


Mike Motion, Adherium CEO noted: “I am pleased to announce Geoff’s appointment as CTO. Geoff brings 25 years’ experience in innovative information and data management along with experience in delivering commercial connected device technologies and telehealth across multiple international markets.


Geoff’s appointment marks an important step as we progress our R&D device and software platform development with Planet Innovation in Melbourne and further strengthens Adherium’s executive leadership team.”


This appointment follows the announcement and approval by shareholders of BioScience Managers Translation Fund 1 investing $5 million in Adherium to progress the development of Adherium’s sensor device portfolio and software platform in Australia.


“I am delighted to take on the role of CTO and be part of the team that executes our strategy that will improve patients’ lives and deliver shareholder value,” said Geoff Feakes. “The relevance and adoption of telehealth and remote patient monitoring has been accelerated by COVID-19 and its role in managing vulnerable patients in healthcare systems.”


“Alongside reimbursement systems now in place in the USA for remote patient monitoring and telehealth Adherium is in a strong position to execute its focused provider and payer strategy. Adherium has a robust technology that provides a foundation upon which I intend to build, bringing into the Company my international experience in developing commercially focused connected integrated solutions across a number of therapeutic areas. I am looking forward to leading our team in partnership with Planet Innovation with a clear development roadmap in inhaled medication device coverage including physiological data reporting.”

Geoff Feakes will be based in Melbourne and report to the CEO, Mike Motion.


About Geoff Feakes
Geoff joins Adherium with more than 25 years of information technology governance, service provision and management, as well as solution innovation and technology leadership across Australia and internationally including the USA, Europe and Asia. In recent years Geoff has been Tunstall APAC’s Chief Technology Officer, Tunstall Group’s Global Technical Director of Health, Global Technical Director (IT Services), as well as Tunstall Group’s Chief Information Officer. Across these roles his responsibilities have included the executive leadership and vision of Tunstall’s Global Remote Patient Monitoring platform and solutions; including product roadmap, development, and solution delivery; product innovation and realization, and the IT and technology strategies. Adding to this Geoff has been responsible for the delivery of quality and project management services and the regulatory oversight of Tunstall’s Health solutions globally.

Geoff is a board member and Vice Chair of Australia’s Personal Emergency Response Services Limited (PERSL), committee member of the Medical Technology Association of Australia (MTAA) Industry Committee and the Connected Health Advisory Group (CHAG).


About Adherium (ASX: ADR)
Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium’s Hailie® solution is designed to achieve better adherence for patients and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user when it is time to take doses, and by providing physicians access to usage history to better understand patients’ patterns in their asthma and COPD. These tools ultimately enable people who live with asthma or COPD to more easily manage their condition alongside their physician. Learn more at adherium.com. Learn more at adherium.com.


The release of this announcement was authorised by the Adherium Board of Directors.


Enquiries:

Rudi Michelson 
Monsoon Communications 
+61 3 9620 3333 
+61 (0)411 402 737
rudijohnmichelson@gmail.com

Mike Motion
Adherium
+44 7917 688801
investors@adherium.com